Mr. Avniel said the three tests will differentiate squamous from non-squamous cell lung cancer; differentiate mesothelioma from adenocarcinoma; and identify the origin of a tumor in cancer of unknown primary (CUP). These tests, applying Rosetta Genomics microRNA technology, will be validated and offered by clinical laboratories that are state-licensed and CLIA-certified, as applicable.
The tests based on Rosetta Genomics' microRNA technology share three common features. First, they are designed to offer clinicians standardized, objective diagnostic information. Second, they are designed to assist clinicians in determining the most appropriate treatment for patients. Third, the tests are backed by a strong pharmacoeconomic rationale. "We are constantly expanding our diagnostic pipeline, both through collaborations as well as internally, with tests aimed to fulfill these three objectives," Mr. Avniel said.
Mr. Avniel noted that 2007 also saw continued progress in Rosetta Genomics' microRNA-based therapeutics program for liver cancer, conducted in collaboration with Isis Pharmaceuticals, with in vivo studies initiated.
Mr. Avniel added that concerning intellectual property, Rosetta Genomics "has continued to strengthen its portfolio this year, with 2 patents issued, 2 patents allowed, and 22 applications under active examination, as well as four new patent applications filed during Q4 of 2007."
Operating loss for the fourth quarter of 2007 was $3.5 million
(including a non-cash expense of $311,000 related to stock based
compensation), compared with an operating loss of $2.2 million (including a
non-cash expense of $302,000 related to stock based compensation), for the
corresponding quarter of 2006. Operating loss for the year ended December
31, 2007 was $11 million (including a non-cash expense of $1 million
related to stock based compensation), com
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved